在慢性骨髓性白血病中,决定对氨酸激酶抑制剂的坚持的危险因素
Betel Del Rosario García1, María Micaela Viña Romero1, Virginia González Rosa2
1Servicio de Farmacia, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, España.
概括
慢性髓性白血病 (CML) 患者接受氨酸激酶抑制剂 (TKIs) 治疗时,表现出低于最佳的坚持,影响治疗的有效性. 患者的教育和就业状况是影响TKI治疗的关键因素.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 氨酸激酶抑制剂 (TKIs) 已经彻底改变了慢性髓性白血病 (CML) 治疗.
- 患者的坚持对于高效的CML疗法的临床益处至关重要.
研究的目的:
- 分析接受TKI治疗的CML患者的坚持率.
- 确定与CML患者TKI不遵守相关的人口和社会经济因素.
主要方法:
- 在8个月的时间里进行了前性,观察性,多中心研究.
- 包括接受TKI治疗的CML患者参加医院门诊药房服务.
- 通过简化药物坚持调查问卷 (SMAQ) 和治疗发行记录评估了坚持.
主要成果:
- 招募了130名CML患者,56.9%的患者表现出足够的坚持.
- 在imatinib,nilotinib和dasatinib中,坚持率相似.
- 较低的教育水平和失业率是不遵守的重要预测因素 (p<0.05).
结论:
- 遵守技术知识说明是CML管理持续有效性的关键因素.
- 大约一半的CML患者对TKI治疗的坚持不够.
- 就业状况和教育程度是TKI在CML中的坚持的重要决定因素.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Factors Affecting Protein-Drug Binding: Patient-Related Factors
73
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
73
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Factors Affecting Protein-Drug Binding: Drug-Related Factors
129
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
129
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Chronic Kidney Disease II: Clinical Manifestations
16
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
16


